Jaguar Health's Napo Pharma Announces Expanded-Access Benefit Of Crofelemer In Congenital Sodium Diarrhea Patient; Plans To File NDA For Crofelemer For MVID In Mid-2027

Loading news article.

Jaguar Health's Napo Pharma Announces Expanded-Access Benefit Of Crofelemer In Congenital Sodium Diarrhea Patient; Plans To File NDA For Crofelemer For MVID In Mid-2027 | WAPE

Jaguar Health's Napo Pharma Announces Expanded-Access Benefit Of Crofelemer In Congenital Sodium Diarrhea Patient; Plans To File NDA For Crofelemer For MVID In Mid-2027

Article summary

Related companies

Analyzed by WAPE AI.

Comments —